Susan E Andrade

Summary

Publications

  1. ncbi Adherence with urate-lowering therapies for the treatment of gout
    Leslie R Harrold
    Department of Medicine, The Meyers Primary Care Institute, Worcester, MA 01605, USA
    Arthritis Res Ther 11:R46. 2009
  2. ncbi Liver function testing in patients on HMG-CoA reductase inhibitors
    Susan E Andrade
    Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA
    Pharmacoepidemiol Drug Saf 12:307-13. 2003
  3. ncbi Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients
    Susan M Abughosh
    Pharmacoepidemiology and Pharmacoeconomics Program, University of Rhode Island, Kingston, Rhode Island 02881, USA
    J Manag Care Pharm 10:404-11. 2004
  4. ncbi Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
  5. ncbi Communicating safety information to physicians: an examination of dear doctor letters
    Kathleen M Mazor
    Meyers Primary Care Institute, Worcester, MA 01605, USA
    Pharmacoepidemiol Drug Saf 14:869-75. 2005
  6. ncbi FDA drug prescribing warnings: is the black box half empty or half full?
    Anita K Wagner
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Pharmacoepidemiol Drug Saf 15:369-86. 2006
  7. ncbi Risk factors for statin-associated rhabdomyolysis
    Stephanie Schech
    Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA
    Pharmacoepidemiol Drug Saf 16:352-8. 2007
  8. ncbi Outpatient use of cardiovascular drugs during pregnancy
    Susan E Andrade
    Meyers Primary Care Institute University of Massachusetts Medical School, Fallon Foundation, and Fallon Community Health Plan, Worcester, MA 01605, USA
    Pharmacoepidemiol Drug Saf 17:240-7. 2008

Collaborators

  • D J Graham
  • Anita K Wagner
  • Leslie R Harrold
  • Stephanie Schech
  • Kathleen M Mazor
  • Jerry H Gurwitz
  • Susan M Abughosh
  • Becky A Briesacher
  • Robert A Yood
  • Marsha A Raebel
  • Ira S Ockene
  • Hassan Fouayzi
  • Margaret Burgess
  • K Arnold Chan
  • Richard Platt
  • David Blough
  • Deborah Shatin
  • Judy Staffa
  • Lois La Grenade
  • Andy Stergachis
  • Jill Auger
  • Leslie Fish
  • Stephen J Kogut
  • Paul Larrat

Detail Information

Publications8

  1. ncbi Adherence with urate-lowering therapies for the treatment of gout
    Leslie R Harrold
    Department of Medicine, The Meyers Primary Care Institute, Worcester, MA 01605, USA
    Arthritis Res Ther 11:R46. 2009
    ..Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout...
  2. ncbi Liver function testing in patients on HMG-CoA reductase inhibitors
    Susan E Andrade
    Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA
    Pharmacoepidemiol Drug Saf 12:307-13. 2003
    ..We sought to determine the frequency and patterns of LFT screening in patients receiving HMG-CoA reductase inhibitors...
  3. ncbi Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients
    Susan M Abughosh
    Pharmacoepidemiology and Pharmacoeconomics Program, University of Rhode Island, Kingston, Rhode Island 02881, USA
    J Manag Care Pharm 10:404-11. 2004
    ..To determine the effects of lipid-lowering agent (LLA) class and drug plan design option on persistence with LLAs among elderly patients enrolled in a managed care plan...
  4. ncbi Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
    ..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
  5. ncbi Communicating safety information to physicians: an examination of dear doctor letters
    Kathleen M Mazor
    Meyers Primary Care Institute, Worcester, MA 01605, USA
    Pharmacoepidemiol Drug Saf 14:869-75. 2005
    ..This study examined whether content, organization, and formatting of dear doctor letters (DDLs) influences physicians' responses to the letters...
  6. ncbi FDA drug prescribing warnings: is the black box half empty or half full?
    Anita K Wagner
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Pharmacoepidemiol Drug Saf 15:369-86. 2006
    ..The purpose of the present study was to assess the frequency of use of BBW medications in ambulatory care and prescribing compliance with BBW recommendations...
  7. ncbi Risk factors for statin-associated rhabdomyolysis
    Stephanie Schech
    Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA
    Pharmacoepidemiol Drug Saf 16:352-8. 2007
    ..To identify and characterize risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy...
  8. ncbi Outpatient use of cardiovascular drugs during pregnancy
    Susan E Andrade
    Meyers Primary Care Institute University of Massachusetts Medical School, Fallon Foundation, and Fallon Community Health Plan, Worcester, MA 01605, USA
    Pharmacoepidemiol Drug Saf 17:240-7. 2008
    ..To provide information on the prevalence of use of cardiovascular drugs, some of which may have fetotoxic or teratogenic effects, in the outpatient setting among pregnant women in the United States...